title: Outcome of metastatic non-small cell lung carcinoma patients receiving docetaxelcisplatin combination chemotherapy: single institution experience.
abstract: OBJECTIVE
  Despite advances in the detection and treatment, the long-term survival of patients with advanced nonsmall cell lung cancer (NSCLC) remains poor, with a 5-year overall survival (OS) of less than 5%. We conducted this observational study to determine the influence of docetaxel plus cisplatin combination chemotherapy on response, time to progression (TTP) and OS, and to evaluate its tolerability in chemotherapy-naïve patients with metastatic NSCLC.
  
  
  METHODS
  Patients with histologically or cytologically confirmed stage IV NSCLC who met the following criteria were eligible for the study: no previous chemotherapy, Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2, objectively measurable disease, adequate bone marrow reserve, normal hepatic and renal function. Patients received docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2), both given on day 1. Cycles were repeated every 3 weeks and a total of 4-6 cycles were scheduled to be administered.
  
  
  RESULTS
  50 consecutive eligible patients were enrolled into the study. Median follow-up time was 6 months (range 1-21). Median age was 61.5 years (range 39-75). Forty-eight (96%) patients were male. Histological type was squamous cell carcinoma in 21 (42%) patients, adenocarcinoma in 11 (22%) and undifferentiated carcinoma in 18 (36%). The median OS time was 16 months (range 7.1-24.9; 95% CI: 8-24). One-year OS was 56.3%. Overall response rate was 44% with 40% partial (PR) and 4% complete responses (CR). Twenty-eight percent of patients had stable disease (SD) and 28% progressive disease (PD). The median TTP was 4 months (range 2-13; 95% CI: 2.4-5.5).
  
  
  CONCLUSIONS
  Docetaxel/cisplatin combination demonstrated efficacy comparable to other platinum-containing doublets.
authors: Kartal Research and Training Hospital, Department of Oncology, Istanbul, Turkey.
authors: M
authors: M
authors: Kocak
authors: A
authors: A
authors: Mayadagli
authors: A
authors: A
authors: Ozkan
authors: C
authors: C
authors: Parlak
authors: O
authors: O
authors: Demir
authors: A
authors: A
authors: Marti
authors: M
authors: M
authors: Dogan Eren
authors: S
authors: S
authors: Kaya
authors: M
authors: M
authors: Gumus
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin